Lutetium-177 vipivotide tetraxetan for treating PSMA-positive hormone-relapsed metastatic prostate cancer after 2 or more treatments
Technology appraisal guidance
Reference number: TA930
Published:
Please note that following on from advice received from the company the timelines for this appraisal have been revised.
For information, we anticipate that the appraisal will now begin during early November 2021.